Edition:
United Kingdom

Evotec AG (EVTG.DE)

EVTG.DE on Xetra

17.31EUR
10 Dec 2018
Change (% chg)

-- (--)
Prev Close
€17.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,655,202
52-wk High
€23.36
52-wk Low
€12.06

Latest Key Developments (Source: Significant Developments)

Evotec And Leo Pharma Form Skin Drug Discovery Alliance
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC AND LEO PHARMA FORM DRUG DISCOVERY ALLIANCE TARGETING DERMATOLOGICAL CONDITIONS.COLLABORATION GOAL IS TO GENERATE NEW LEADS AGAINST INNOVATIVE TARGETS FOR A RANGE OF DERMATOLOGICAL CONDITIONS AND INITIALLY RUNS FOR TWO YEARS.EVOTEC'S INTEGRATED DISCOVERY SCIENTISTS WILL WORK IN A JOINT TEAM WITH SCIENTISTS FROM LEO PHARMA.ALLIANCE WILL RECEIVE FURTHER SUPPORT WITH HIGH-VALUE DRUG DEVELOPMENT AND DISCOVERY ADME-TOX SERVICES.NO FINANCIAL DETAILS OF THIS FEE-FOR-SERVICE COLLABORATION WERE DISCLOSED.  Full Article

Evotec confirms 2018 outlook, appoints Craig Johnstone COO
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Evotec AG ::9M REVENUE ROSE 57 PERCENT TO 270 MILLION EUR.57% INCREASE IN GROUP REVENUES, 77% INCREASE IN ADJUSTED GROUP EBITDA.STRONG OUTLOOK FOR 2018 CONFIRMED AND GOOD UNDERLYING BUSINESS INDICATIONS FOR 2019.GROUP REVENUES: 57% INCREASE TO EUR 270.0 M (9M 2017: EUR 171.5 M).EVT EXECUTE REVENUES UP 53% TO EUR 254.3 M (9M 2017: EUR 165.8 M);.EVT INNOVATE REVENUES UP 55% TO EUR 51.3 M (9M 2017: EUR 33.2 M).ADJUSTED GROUP EBITDA UP 77% TO EUR 68.7 M (9M 2017: EUR 38.9 M).ADJUSTED EBITDA FOR EVT EXECUTE OF EUR 62.1 M (9M 2017: EUR 41.4 M).ADJUSTED EBITDA FOR EVT INNOVATE OF EUR 6.6 M (9M 2017: EUR (2.5) M).GROUP RESEARCH AND DEVELOPMENT EXPENSES INCREASE OF 67% TO EUR 20.9 M (9M 2017: EUR 12.5 M).STRONG LIQUIDITY POSITION OF EUR 168.6 M EVEN AFTER 50% (EUR 70 M).CLINICAL PHASE I AND PHASE II STARTS AND GOOD PROGRESS WITHIN ONGOING ALLIANCES (E.G. BAYER ENDOMETRIOSIS/CHRONIC COUGH ALLIANCE).SIGNING OF MULTIPLE NEW AND EXTENDED DRUG DISCOVERY AND DEVELOPMENT AGREEMENTS (E.G. CHDI, NOVO NORDISK, FERRING (AFTER PERIOD-END).NEW CONTRACTS AND INCREASED DEMAND FOR INDIGO SOLUTIONS AND DEVELOPMENT SERVICES (E.G. ANKAR, ASTEX, INFLAZOME, YUMANITY).STRONG PERFORMANCE ACROSS ALL BUSINESS AND SERVICE LINES (E.G. HIGH-THROUGHPUT ADME-TOX TESTING AT CYPROTEX, AN EVOTEC COMPANY).CHANGE IN MANAGEMENT BOARD AS OF 01 JANUARY 2019: APPOINTMENT OF DR CRAIG JOHNSTONE AS NEW COO; DR MARIO POLYWKA RETIRING FROM EVOTEC.GUIDANCE 2018 CONFIRMED.  Full Article

Evotec H1 Revenue Rises By 67 Pct
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Evotec AG ::H1 REVENUE ROSE 67 PERCENT TO 173.8 MILLION EUR.67% INCREASE IN GROUP REVENUES, 47% INCREASE IN ADJUSTED GROUP EBITDA.GROUP REVENUES: 67% INCREASE TO EUR 173.8 M (H1 2017: EUR 104.3 M).GUIDANCE ON GROUP REVENUES - GROWTH OF >30% CONFIRMED.GUIDANCE ON ADJUSTED GROUP EBITDA - GROWTH OF APPROX. 30% CONFIRMED.GUIDANCE ON RESEARCH AND DEVELOPMENT EXPENSES INCREASED - RESEARCH AND DEVELOPMENT EXPENSES FOR 2018 WILL INCREASE TO EUR 35-45 M.  Full Article

Evotec Repays Half of 140 Mln Euro Acquisition Loan
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC REPAYS 50% OF EUR 140 M ACQUISITION LOAN.EXPECTS REPAYMENT TO SHOW A SIGNIFICANTLY POSITIVE EFFECT ON NET DEBT RATIO IN COMPANY'S RESULTS.  Full Article

Evotec AG Will Be Renamed Evotec SE
Wednesday, 20 Jun 2018 

June 20 (Reuters) - EVOTEC AG ::WILL BE RENAMED EVOTEC SE.  Full Article

Evotec And Celgene Enter Into Strategic Oncology Partnership
Monday, 21 May 2018 

May 21 (Reuters) - Evotec Ag ::DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP.UNDER TERMS OF AGREEMENT, EVOTEC WILL RECEIVE AN UPFRONT PAYMENT OF $65 MILLION.CELGENE RECEIVES EXCLUSIVE OPT-IN RIGHTS TO LICENSE WORLDWIDE RIGHTS TO ALL PROGRAMMES DEVELOPED WITHIN THIS COLLABORATION.EVOTEC MAY BE ELIGIBLE TO RECEIVE SIGNIFICANT MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES ON EACH LICENSED PROGRAMME.  Full Article

Evotec Affirms Guidance After Q1 Results
Wednesday, 9 May 2018 

May 9 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE.Q1 REVENUE ROSE 55 PERCENT TO 79 MILLION EUR.55% INCREASE IN GROUP REVENUES.Q1 GROUP REVENUES: 55% INCREASE TO EUR 79.0 M.Q1 ADJUSTED GROUP EBITDA UP 4% TO EUR 14.0 M.FINANCIAL GUIDANCE 2018 CONFIRMED.  Full Article

Evotec, Apeiron Biologics receive milestone payment from Sanofi
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Evotec Ag ::SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​.SAYS ‍MILESTONE PAYMENT OF EUR 3 M WILL BE SPLIT EQUALLY BETWEEN TWO BIOTECH COMPANIES​.SAYS ‍SUCCESS PAYMENT WAS TRIGGERED WHEN PARTNERS SUCCESSFULLY ADVANCED AN UNDISCLOSED, NOVEL IMMUNO-ONCOLOGY SMALL MOLECULE INTO LATE-STAGE PRE-CLINICAL DEVELOPMENT​.SAYS ‍UNDER ALLIANCE, THREE COMPANIES WORK TOGETHER TO IDENTIFY SMALL MOLECULE LEADS AND TARGETS FOR NEXT-GENERATION THERAPIES IN IMMUNO-ONCOLOGY​.  Full Article

Evotec affirms guidance after 9-month core profit jump
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Evotec Ag :9M revenue rose 42 percent to 170.9 million eur.‍9M adjusted group EBITDA up 28% to eur 39.3 m (9m 2016: eur 30.6 m)​.Says ‍guidance 2017 confirmed​.  Full Article

Germany's Evotec to acquire U.S.-based Aptuit for 256 mln euros
Sunday, 30 Jul 2017 

July 30 (Reuters) - Evotec AG :Evotec to acquire Aptuit, expanding leadership in external innovation.Consideration of about 256 million euros to be paid in cash from Evotec's balance sheet and through debt financing at highly attractive terms.  Full Article

German stocks - Factors to watch on Nov. 13

BERLIN, Nov 13 The following are some of the factors that may move German stocks on Tuesday: